Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

So far, Retatrutide, developed by Eli Lilly, has achieved an efficacy rate of 24%, ahead of CagriSema. Previously, the biggest challenge facing Novo Nordisk and Eli Lilly — beyond their rivalry — was ...

When it comes to weight loss drugs ... The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase ...

The FDA has not approved weight loss patches because no evidence of their effectiveness and safety is available. As the FDA does not control these products, it does not regulate the quantity or ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the ... I have no business relationship with any company ...

A big catalyst for the stock could come in June when the company is expected to provide more detailed clinical results for CagriSema, its next-generation weight loss drug. Investors were ...

The West Virginia Mountaineers (12-4, 3-2) fell to the No. 10 Houston Cougars (13-3 ... Tony Caridi for his initial thoughts on the loss in Houston. I really thought the way the game played ...

There are no quick fixes and rushing into weight loss may do more harm than good. Therefore, one must remember that what one works for one, may not be equally optimal for another body type.